Herceptin Approved For Every-Three-Week Dosing In Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Trastuzumab is cleared for adjuvant treatment in HER2-positive node-positive and node-negative breast cancer as a single agent or combined with hormonal therapy.
You may also be interested in...
Herceptin Approved In Two New Regimens
Carboplatin substitutes for anthracyclines to reduce cardiac risk.
Herceptin Approved In Two New Regimens
Carboplatin substitutes for anthracyclines to reduce cardiac risk.
Genentech Plans Herceptin Early-Stage Breast Cancer Submission
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.